PRTH
PRTH
NASDAQ · Financial Services

Priority Technology Holdings

Small-Cap Stocks Stocks Under $10 Bank & Financial Stocks
$7.18
+0.02 (+0.28%)
As of Jul 4, 10:26 PM ET ·
PRTH News2 articles
Replimune Surges 85% on FDA Priority Review for Melanoma Drug
Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.
Markets
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
Earnings